HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 8, August 2016 – Novel Technologies for Antibody Drug Discovery in Japan       » Global Experts Convene to Discuss China's Plan for Diabetes Prevention and Rehabilitation in 2016       » Butterflies Offer Climate Scientists Ecological Insights       » Thermal Stability of Camelid Single Domain VHH Antibody       » That Gut Feeling: How A Healthy Digestive System Has Everything To Do With It       » World Heart Day - At the Heart of Health      
BIOBOARD - CANADA
Genome British Columbia researchers closing in on chlamydia vaccine

Chlamydia is one of the most widespread sexually transmitted bacterial diseases in the world, causing an estimated 92 million infections globally per year. With existing treatment programs failing to stem the spread of infection, a vaccine is widely acknowledged as the only way to prevent the suffering and significant infertility caused by Chlamydia (C. trachomatis), the causative agent for the disease.

Recent advances in mass spectrometry technology, proteomics, genomics and Chlamydia immunology have resulted in significant advancements towards vaccine development. Through its Proof-of-Concept (POC) program Genome British Columbia (Genome BC) is funding the necessary pre-clinical studies to move a novel Chlamydia vaccine to human trials.

Genome British Columbia is a catalyst for the life sciences cluster on Canada's West Coast.

"Investment into public health is of significant importance to our province," says Dr. Alan Winter, President and CEO of Genome BC. "Genome BC remains committed to funding research that will result in practical, societal benefits and these projects demonstrate that."

Dr. Robert Brunham of the BC Centre for Disease Control is leading the POC project entitled "Accelerating the Development of a Novel Outer Membrane Protein Based Vaccine Against Chlamydia Infection". The project, in partnership with the Canadian not-for-profit Pan-Provincial Vaccine Enterprise Inc. (PREVENT), is expected to run over 21 months and will also include US Food and Drug Administration filings for anticipated clinical grade vaccine production.

The market profile for a Chlamydia vaccine is expected to be similar to the HPV vaccine currently on the market, which is now part of publicly funded healthcare and beginning to reduce HPV rates among Canadians.

Source: Marketwired News

Click here for the complete issue.

NEWS CRUNCH  
news CPhI's Pre-Connect Congress outlines current trends in pharma
news World Population Day 2016
news NUS Student Clinches Top Prize at National Smart Mapping Competition with Cutting-Edge Food Security Solution
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Big Data in Healthcare
December:
Evidence-based TCM
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy